{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:40:19Z","timestamp":1793252419626,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jconrel.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T21:34:16Z","timestamp":1731965656000},"page":"162-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective"],"prefix":"10.1016","volume":"377","author":[{"given":"Burcu","family":"Binici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rattray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Perrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.11.010_bb0005","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0010","first-page":"1","article-title":"Nanomaterial delivery systems for mrna vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01265-9","article-title":"Immunogenic amines on lipid nanoparticles","author":"Sharma","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0020","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d, Nat","author":"Chaudhary","year":"2024","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0030","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0045","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1039\/C8TX00005K","article-title":"Correlation of the cytotoxic effects of cationic lipids with their headgroups","volume":"7","author":"Cui","year":"2018","journal-title":"Toxicol. Res. (Camb.)"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0075","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0090","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","article-title":"Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors","volume":"357","author":"Anthiya","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0115","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4994","article-title":"Fluorescent labeling and imaging of IL-22 mRNA-loaded lipid nanoparticles","volume":"14","author":"Mow","year":"2024","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102325","article-title":"The dynamic process of mRNA delivery by lipid nanoparticles in vivo","volume":"57","author":"Ma","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1039\/D4PM00128A","article-title":"Tailoring lipid nanoparticle dimensions through manufacturing processes","volume":"1","author":"McMillan","year":"2024","journal-title":"RSC Pharmaceut."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115065","article-title":"In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy","volume":"165","author":"Escalona-Rayo","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0140","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/vaccines11101580","article-title":"The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0145","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/jacs.2c10670","article-title":"Iterative design of ionizable lipids for intramuscular mRNA delivery","volume":"145","author":"Tilstra","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202300285","article-title":"Branching ionizable lipids can enhance the stability, fusogenicity, and functional delivery of mRNA","volume":"3","author":"Hashiba","year":"2023","journal-title":"Small Sci."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201805097","article-title":"Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH","volume":"15","author":"Hajj","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0160","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.01.001","article-title":"Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo","volume":"295","author":"Sato","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0170","doi-asserted-by":"crossref","first-page":"15832","DOI":"10.1021\/acsami.3c18830","article-title":"Harnessing RNA technology to advance therapeutic vaccine antigens against Chagas disease","volume":"16","author":"Mancino","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0175","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0180","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0185","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes","volume":"32","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.11.010_bb0190","article-title":"A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery","volume":"10","author":"Naidu","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2024.11.010_bb0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T21:27:47Z","timestamp":1734643667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924007557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S0168365924007557"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.010","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}